Literature DB >> 30578335

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.

Vincent Cottin1,2, Nikhil A Hirani3, David L Hotchkin4, Anoop M Nambiar5, Takashi Ogura6, María Otaola7, Dirk Skowasch8, Jong Sun Park9, Hataya K Poonyagariyagorn4, Wim Wuyts10, Athol U Wells11,2.   

Abstract

Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, decreased quality of life and, potentially, early death. Idiopathic pulmonary fibrosis may be regarded as a model for other progressive-fibrosing ILDs. Here we focus on other ILDs that may present a progressive-fibrosing phenotype, namely idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, connective tissue disease-associated ILDs (e.g. rheumatoid arthritis-related ILD), fibrotic chronic hypersensitivity pneumonitis, fibrotic chronic sarcoidosis and ILDs related to other occupational exposures. Differential diagnosis of these ILDs can be challenging, and requires detailed consideration of clinical, radiological and histopathological features. Accurate and early diagnosis is crucial to ensure that patients are treated optimally.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 30578335     DOI: 10.1183/16000617.0076-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  89 in total

1.  Novel Thoracic MRI Approaches for the Assessment of Pulmonary Physiology and Inflammation.

Authors:  Jonathan P Brooke; Ian P Hall
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.

Authors:  Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Multi-scale models of lung fibrosis.

Authors:  Julie Leonard-Duke; Stephanie Evans; Riley T Hannan; Thomas H Barker; Jason H T Bates; Catherine A Bonham; Bethany B Moore; Denise E Kirschner; Shayn M Peirce
Journal:  Matrix Biol       Date:  2020-05-11       Impact factor: 11.583

Review 4.  [Treatment of systemic sclerosis-associated interstitial lung disease].

Authors:  A Prasse; F Bonella; U Müller-Ladner; T Witte; N Hunzelmann; J Distler
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

5.  The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases.

Authors:  Mathew Suji Eapen; Archana Vijay Gaikwad; Isobel E Thompson; Wenying Lu; Stephen Myers; Pawan Sharma; Sukhwinder Singh Sohal
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

6.  Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

Authors:  Hideaki Yamakawa; Shintaro Sato; Emiri Tsumiyama; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Teppei Kamikawa; Masanobu Horikoshi; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hidekazu Matsushima
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

Review 7.  Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.

Authors:  Yvette N Lamb
Journal:  Drugs       Date:  2021-03-25       Impact factor: 9.546

8.  Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease.

Authors:  Sara Remuzgo-Martínez; Fernanda Genre; Verónica Pulito-Cueto; Belén Atienza-Mateo; Víctor Manuel Mora Cuesta; David Iturbe Fernández; Sonia María Fernández Rozas; Leticia Lera-Gómez; Pilar Alonso Lecue; María Piedad Ussetti; Rosalía Laporta; Cristina Berastegui; Amparo Solé; Virginia Pérez; Alicia De Pablo Gafas; Oreste Gualillo; José Manuel Cifrián; Raquel López-Mejías; Miguel Ángel González-Gay
Journal:  Biomedicines       Date:  2021-04-22

9.  Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups.

Authors:  Grace Hyun J Kim; Stephan S Weigt; John A Belperio; Matthew S Brown; Yu Shi; Joshua H Lai; Jonathan G Goldin
Journal:  Eur Radiol       Date:  2019-08-26       Impact factor: 5.315

Review 10.  Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

Authors:  John N Shumar; Abhimanyu Chandel; Christopher S King
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.